Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandra Gomez-Cadena

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Frontiers in Medicine|September 26, 2022
Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)Claudia Urueña, Ricardo Ballesteros-Ramírez, Alejandra Gomez-Cadena, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
Nature Communications|February 21, 2026
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancerMaryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Frontiers in Medicine|September 26, 2022
Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)Claudia Urueña, Ricardo Ballesteros-Ramírez, Alejandra Gomez-Cadena, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
Nature Communications|February 21, 2026
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancerMaryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Pageof 2